Crohn's Disease Clinical Trials in Houston, Texas

9 studies are recruiting for crohn's disease in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Integrity Advanced Therapeutics /ID# 283871, Houston, Texas

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Baylor College of Medicine Medical Center ( Site 5020), Houston, Texas

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Kelsey Research Foundation, Houston, Texas

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

4. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

   The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   The University of Texas Health Science Center at Houston, Houston, Texas

   Locations

   48 in total

   Run by

   Takeda

   See if you can join NCT06045754 on ClinicalTrials.gov

5. A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

   This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   The University of Texas Health Science Center at Houston, Houston, Texas

   Locations

   225 in total

   Run by

   Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

   See if you can join NCT06226883 on ClinicalTrials.gov

6. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Houston Methodist Hospital /ID# 265533, Houston, Texas

   Locations

   255 in total

   Run by

   AbbVie

   See if you can join NCT06548542 on ClinicalTrials.gov

7. Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

   This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Ko…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   15 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT03256240 on ClinicalTrials.gov

8. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Texas Children's Hospital - Baylor - PIN, Houston, Texas

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov

9. A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

   This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Mirador Therapeutics Selected Site, Houston, Texas

   Locations

   66 in total

   Run by

   Mirador Therapeutics, Inc.

   See if you can join NCT07113522 on ClinicalTrials.gov